The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia

E. J. Ayres, J. M. Hoeg, Kent R Bailey, J. G. Bieri

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalDrug-Nutrient Interactions
Volume4
Issue number4
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia'. Together they form a unique fingerprint.

  • Cite this